Literature DB >> 24942794

Usefulness of high mobility group box 1 protein as a plasma biomarker in patient with peripheral artery disease.

Susumu Oozawa1, Shunji Sano, Masahiro Nishibori.   

Abstract

Atherosclerosis is often associated with chronic vascular inflammation. High-mobility group box 1 protein (HMGB1) plays various roles, not only as a transcriptional regulatory factor in the nucleus, but also as an inflammatory mediator. A previous study suggested that fibrinogen is an important factor associated with atherosclerosis progression. The present study was performed to examine the levels of plasma HMGB1 protein in atherosclerosis patients. We studied 24 patients with peripheral artery disease (PAD) with atherosclerosis, and 10 healthy controls. We found that the concentrations of HMGB1 were increased in the plasma of the patients with atherosclerosis, and there were significant correlations between the plasma HMGB1 and fibrinogen levels. Plasma HMGB1 may play a key role in the pathogenesis of clinical and experimental atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24942794     DOI: 10.18926/AMO/52656

Source DB:  PubMed          Journal:  Acta Med Okayama        ISSN: 0386-300X            Impact factor:   0.892


  8 in total

Review 1.  Biomarkers of vascular disease in diabetes: the adipose-immune system cross talk.

Authors:  Federico Biscetti; Elisabetta Nardella; Andrea Leonardo Cecchini; Andrea Flex; Raffaele Landolfi
Journal:  Intern Emerg Med       Date:  2020-01-09       Impact factor: 3.397

Review 2.  Role of High Mobility Group Box 1 in Cardiovascular Diseases.

Authors:  Souad Belmadani; Khalid Matrougui
Journal:  Inflammation       Date:  2022-04-07       Impact factor: 4.657

3.  High-Mobility Group Box-1 Is Associated With Obesity, Inflammation, and Subclinical Cardiovascular Risk Among Young Adults: A Longitudinal Cohort Study.

Authors:  Li Chen; Haidong Zhu; Shaoyong Su; Gregory Harshfield; Jennifer Sullivan; Clinton Webb; James A Blumenthal; Xiaoling Wang; Ying Huang; Frank A Treiber; Gaston Kapuku; Wenjun Li; Yanbin Dong
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-08-20       Impact factor: 8.311

4.  Serum high mobility group box-1 and osteoprotegerin levels are associated with peripheral arterial disease and critical limb ischemia in type 2 diabetic subjects.

Authors:  Silvia Giovannini; Giovanni Tinelli; Federico Biscetti; Giuseppe Straface; Flavia Angelini; Dario Pitocco; Luciana Mucci; Raffaele Landolfi; Andrea Flex
Journal:  Cardiovasc Diabetol       Date:  2017-08-08       Impact factor: 9.951

Review 5.  Outcomes of Lower Extremity Endovascular Revascularization: Potential Predictors and Prevention Strategies.

Authors:  Federico Biscetti; Elisabetta Nardella; Maria Margherita Rando; Andrea Leonardo Cecchini; Antonio Gasbarrini; Massimo Massetti; Andrea Flex
Journal:  Int J Mol Sci       Date:  2021-02-18       Impact factor: 5.923

Review 6.  Graphene-Based Biosensors for Molecular Chronic Inflammatory Disease Biomarker Detection.

Authors:  Isidro Badillo-Ramírez; Yojana J P Carreón; Claudia Rodríguez-Almazán; Claudia M Medina-Durán; Selene R Islas; José M Saniger
Journal:  Biosensors (Basel)       Date:  2022-04-14

Review 7.  Vascular Stress Signaling in Hypertension.

Authors:  Stephanie M Cicalese; Josiane Fernandes da Silva; Fernanda Priviero; R Clinton Webb; Satoru Eguchi; Rita C Tostes
Journal:  Circ Res       Date:  2021-04-01       Impact factor: 17.367

8.  Effects of Etanercept against Transient Cerebral Ischemia in Diabetic Rats.

Authors:  Naohiro Iwata; Hiroko Takayama; Meiyan Xuan; Shinya Kamiuchi; Hirokazu Matsuzaki; Mari Okazaki; Yasuhide Hibino
Journal:  Biomed Res Int       Date:  2015-11-19       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.